Risk Factors Analysis and Pharmaceutical Care on One Case with Nephrotic Syndrome and Glucocorticoidinduced Osteonecrosis
PAN Yu-hua1, LAO Hai-yan1, WANG Xiao-xing2, TANG Kun2*
1.Department of Pharmacy, Guangdong General Hospital, Guangzhou Academy of Medical Sciences, Guangzhou 510080, China; 2.Department of Pharmacy,China-Japan Friendship Hospital, Bejing 100029, China
Abstract:Objective : To investigate the role of clinical pharmacists in prevention and treatment of patients with nephrotic syndrome complicated by glucocorticoid-induced osteonecrosis.Methods : By reviewing patients' medical records and searching literatures,clinical pharmacists performed evaluation and analysis on risk factors inducing glucocorticoid-induced osteonecrosis in one patient with nephrotic syndrome,provided pharmaceutical care based on the drugs administered and underlying diseases, and formulated preventive measures against the similar risks. Results : An 20 year-old female patient with mininal-change disease was diagnosed as bilateral femoral head necrosis after admission.Reviewed the patient’s medical records, the total dosage she had taken was about 12 300 mg (calculated as methylprednisolone) and the duration is about 1 year. Features of nephrotic syndrome, for example severe hypoproteinemia, hyperlipidemia and hypercoagulability, may increase the risk of glucocorticoid-induced osteonecrosis. The patient was administrated with alendronate, compound danshen dripping pills, warfarin, dipyridamole and rosuvastatin. Conclusion : Clinical pharmacists promptly discover drug-related adverse events during diagnosis and treatment activities, and provide pharmaceutical care on prevention and treatment, which can improve the safety and effectiveness of drug treatment.
潘裕华,劳海燕,王晓星,唐崑. 1 例肾病综合征患者并发激素性骨坏死的风险因素分析与药学监护[J]. 临床药物治疗杂志, 2016, 14(3): 76-80.
PAN Yu-hua,LAO Hai-yan,WANG Xiao-xing, TANG Kun. Risk Factors Analysis and Pharmaceutical Care on One Case with Nephrotic Syndrome and Glucocorticoidinduced Osteonecrosis. CLINICAL MEDICATION JOURNAL, 2016, 14(3): 76-80.
[1] 糖皮质激素类药物临床应用指导原则[J]. 中华内分泌代谢杂志,2012, 28(2):171-202.
[2] 中国成人肾病综合征免疫抑制治疗专家组. 中国成人肾病综合征免疫抑制治疗专家共识[J]. 中华肾脏病杂志, 2014, 30(6):467-474.
[3] Samuel S, Bitzan M, Zappitelli M, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in Children[J]. Am J Kidney Dis, 2014 ,63(3):354-362.
[4] 赵德伟,胡永成. 成人股骨头坏死诊疗标准专家共识(2012 年版)[J]. 中华关节外科杂志, 2012, 32(6):18-21.
[5] 李子荣. 股骨头骨坏死的ARCO 分期[J]. 中华外科杂志, 1996,(03):59-60.
[6] 田伟,陈安民. 股骨头坏死[A]. 骨科学[M]. 北京: 人民卫生出版社, 2009:558-582.
[7] Weinstein R S. Glucocorticoid-induced osteonecrosis[J]. Endocrine,2012, 41(2):183-190.
[8] Dilisio M F. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients[J].Orthopedics, 2014, 37(7):e631-663.
[9] 李子荣, 孙伟, 屈辉, 等. 皮质类固醇与骨坏死关系的临床研究[J]. 中华外科杂志, 2005,(16):1048-1053.
[10] Chan K L, Mok C C. Glucocorticoid-induced avascular bone necrosis: diagnosis and management[J]. Open Orthop J, 2012, 6:449-457.
[11] Montella B J, Nunley J A, Urbaniak J R. Osteonecrosis of the femoral head associated with pregnancy. A preliminary report[J]. J Bone Joint Surg Am, 1999, 81(6):790-798.
[12] Kerachian M A, Seguin C, Harvey E J. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action[J]. J Steroid Biochem Mol Biol, 2009,114(3-5):121-128.
[13] 冯锦红, 濮红梅. 肾病综合征并发股骨头坏死的危险因素的探讨[J]. 医药前沿, 2014, (26):102-103.
[14] 焦晨峰, 许书添, 涂远茂, 等. 肾病综合征患者合并无菌性股骨头坏死[J]. 肾脏病与透析肾移植杂志, 2015, 24(4):307-312.
[15] Luo R B, Lin T, Zhong H M, et al. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review[J]. Med Sci Monit, 2014, 20:2439-2447.
[16] Hong Y C, Luo R B, Lin T, et al. Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis[J]. Biomed Res Int, 2014, 2014:716538.
[17] 李超, 尚希福, 贺瑞. 二膦酸盐类药物治疗股骨头坏死的研究进展[J]. 中国骨与关节损伤杂志, 2014, (04):415-416.
[18] Jager M, Zilkens C, Bittersohl B, et al. Efficiency of iloprost treatment for osseous malperfusion[J]. Int Orthop, 2011, 35(5):761-765.
[19] 史风雷. 复方丹参注射液预防激素性股骨头坏死的初步研究[D].济南: 山东中医药大学, 2001.
[20] 黄相杰, 姜红江, 谭远超, 等. 复方丹参缓释系统植入治疗股骨头缺血性坏死的实验研究[J]. 中国矫形外科杂志, 2007, (05):384-386, 402.
[21] Pritchett J W. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids[J]. Clin Orthop Relat Res, 2001,(386):173-178.
[22] Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant[J]. Lupus, 2006, 15(6):354-357.
[23] 康鹏德, 沈彬, 杨静, 等. 抗凝、降脂治疗对预防兔激素型股骨头缺血性坏死的实验研究[J]. 中华关节外科杂志( 电子版),2007, (1):56-61.
[24] 王海燕. 肾病综合征及其治疗[A]. 肾脏病临床概览[M]. : 北京大学医学出版社, 2010:121-130.